Literature DB >> 8490846

Intravascular lymphomatosis. A systemic disease with neurologic manifestations.

J Glass1, F H Hochberg, D C Miller.   

Abstract

BACKGROUND: Intravascular lymphomatosis (IL) is a systemic neoplasm that often involves the nervous system, inducing progressive neurologic deficits in the setting of undiagnosed or quiescent extranodal non-Hodgkin lymphoma.
METHODS: The clinical and pathologic files of the Massachusetts General Hospital and New York University Medical Center and the English language literature were reviewed to identify all reports of intravascular lymphomatosis (angioendotheliomatosis) or other examples of a diffuse proliferation of neoplastic cells filling capillaries, arterioles, and venules.
RESULTS: The authors report seven patients with IL and note 114 patients reported in the literature. Almost two-thirds (63%) of patients had neurologic manifestations, without abnormalities on bone marrow biopsy, chest and abdominal tomographic examinations for adenopathy, and cerebrospinal fluid (CSF) analysis. All patients had one or more of four syndromes, each reflecting a vascular occlusive process: progressive, multifocal cerebrovascular events; paraparesis, pain, and incontinence; a subacute encephalopathy; and peripheral or cranial neuropathies.
CONCLUSIONS: The unexplained presence of any one or more of these neurologic syndromes should alert the physician to the possible presence of this disease.

Entities:  

Mesh:

Year:  1993        PMID: 8490846     DOI: 10.1002/1097-0142(19930515)71:10<3156::aid-cncr2820711043>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

Review 1.  Identification and management of difficult stroke and TIA syndromes.

Authors:  M M Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

2.  A 59 year old man with progressive spinal cord and peripheral nerve dysfunction culminating in encephalopathy: Edinburgh advanced clinical neurology course, 1999.

Authors:  R Al-Shahi; C P Warlow; G H Jansen; C J Frijns; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

Review 3.  Stroke in cancer patients.

Authors:  Teri Nguyen; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

4.  A case of intravascular lymphoma with increased regional cerebral blood flow in I-123 IMP single-photon emission CT.

Authors:  Chihoko Miyazaki; Masaya Mukai; Yuriko Kawaai; Miki Takeda; Norio Katoh; Syunsuke Nagano; Kozoh Kubo; Michifumi Kohno
Journal:  AJNR Am J Neuroradiol       Date:  2004-04       Impact factor: 3.825

5.  Characteristics of intravascular large B-cell lymphoma on cerebral MR imaging.

Authors:  A Yamamoto; Y Kikuchi; K Homma; T O'uchi; S Furui
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-15       Impact factor: 3.825

6.  Paraplegia and sensory deficit caused by angiotropic large cell lymphoma.

Authors:  Marc Legeais; Sophie Gallas; Jean Philippe Cottier; Denis Herbreteau
Journal:  AJNR Am J Neuroradiol       Date:  2004 Nov-Dec       Impact factor: 3.825

7.  Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system.

Authors:  J M Baehring; C Henchcliffe; C J Ledezma; R Fulbright; F H Hochberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

8.  Intravascular large B-cell lymphoma presenting as an isolated cauda equina-conus medullaris syndrome - A case report.

Authors:  Yang Yu; Raghav Govindarajan
Journal:  J Spinal Cord Med       Date:  2018-10-22       Impact factor: 1.985

9.  Intravascular large B-cell lymphoma confirmed by brain biopsy: a case report.

Authors:  Pushpendra Nath Renjen; Nadeem Israr Khan; Yogesh Gujrati; Shakti Kumar
Journal:  BMJ Case Rep       Date:  2013-02-18

Review 10.  A new approach to the diagnosis and treatment of intravascular lymphoma.

Authors:  Joachim M Baehring; Janina Longtine; Fred H Hochberg
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.